Sun Pharma.Inds.

{
  "main_header": {
    "sid": 948699,
    "name": "Sun Pharma.Inds.",
    "stock_name": "Sun Pharma.Inds.",
    "full_name": "Sun Pharmaceutical Industries Ltd",
    "name_url": "stocks-analysis/sun-pharmainds",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,877.95",
    "chg": 14.5,
    "chgp": "0.78%",
    "dir": 1,
    "prev_price": "1,863.45",
    "mcapval": "450,583.11 Cr",
    "mcap": "Large Cap",
    "scripcode": 524715,
    "symbol": "SUNPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE044A01036",
    "curr_date": "Jun 23, 01:26 PM",
    "curr_time": "13:27 PM",
    "last_traded_at": "Jun 23, 01:26 PM IST",
    "bse_nse_vol": "18.26 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 23, 2026",
    "traded_date_str": "2026 06 23",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "MS",
      "url": "https://www.marketsmojo.com/mojostocks#!#top10",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "10,956 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Nears Rs 1,900 Strike",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-surge-in-call-option-activity-amid-bullish-momentum-4068756",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SunPharmaceutic_most_active_stocks_calls_4068756.png",
        "date": "2026-06-23 10:00:15",
        "description": "On 23 Jun 2026, 10,956 call contracts at the Rs 1,900 strike price changed hands on Sun Pharmaceutical Industries Ltd, with the stock closing at Rs 1,892. This near at-the-money activity coincides with a 1.80% gain in the cash market, signalling a strong alignment between options positioning and underlying price momentum."
      },
      {
        "title": "Rs 1,840 Puts — 2.7% Below Current Price — Draw 2,530 Contracts on Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-amid-mixed-market-signals-4068763",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SunPharmaceutic_most_active_stocks_puts_4068763.png",
        "date": "2026-06-23 10:00:15",
        "description": "The stock is trading at Rs 1,892, yet put contracts at the Rs 1,840 strike have surged to 2,530 on 23 Jun 2026, signalling a nuanced options market dynamic for Sun Pharmaceutical Industries Ltd. This activity invites a closer look at whether these puts represent hedging, bearish bets, or put writing."
      },
      {
        "title": "P/E at 35.85 vs Industry's 34.38: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-a-key-nifty-50-constituent-4068545",
        "imagepath": "",
        "date": "2026-06-23 09:21:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Parity</strong></p>\n                <p>The current P/E of 35.85 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> represents a modest premium of approximately 4.3% over the sector average of 34.38. This premium suggests that investors are willing to pay slightly more for the company’s earnings relative to its peers in Pharmaceuticals &amp; Biotechnology. Given the sector’s broad composition, which includes 35 stocks with 19 reporting positive results, 9 flat, and 7 negative, this premium may reflect confidence in the company’s earnings stability and growth prospects. However, the premium is not excessive, indicating a valuation that remains broadly in li..."
      },
      {
        "title": "P/E at 35.38 vs Industry's 34.06: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4066834",
        "imagepath": "",
        "date": "2026-06-22 09:21:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Parity</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> stands at 35.38, slightly above the Pharmaceuticals &amp; Biotechnology industry average of 34.06. This premium, though not extreme, suggests investors are willing to pay a bit more for the stock relative to its peers. The market capitalisation of ₹4,40,086.02 crore places it firmly in the large-cap category, reflecting its established position within the sector.</p>\n                <p>This valuation premium may be interpreted as a reflection of the company’s relative stability and growth prospects within a sector that has seen varied results. However,..."
      },
      {
        "title": "Sun Pharmaceutical Industries Ltd is Rated Buy",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-buy-4066060",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SunPharmaceutic_mojoScore_4066060.png",
        "date": "2026-06-21 10:10:26",
        "description": "Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 8 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 June 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "P/E at 35.16 vs Industry's 33.88: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-key-nifty-50-constituent-amid-institutional-interest-4062827",
        "imagepath": "",
        "date": "2026-06-19 09:21:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Norms</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> at 35.16 is approximately 3.8% higher than the industry average of 33.88. This premium suggests that investors are willing to pay a slight premium for the company’s earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. While not an extreme divergence, this elevated valuation may reflect expectations of sustained earnings growth or perceived stability within a large-cap framework valued at ₹4,40,589.88 crores.</p>\n                <p>However, the premium is not excessive when compared to historical sector valuations, indicati..."
      },
      {
        "title": "P/E at 35.03 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-as-a-key-nifty-50-constituent-amid-positive-institutional-sentiment-4060685",
        "imagepath": "",
        "date": "2026-06-18 09:22:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Norms</strong></p>\n                <p>The current P/E of 35.03 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> stands approximately 4.2% above the Pharmaceuticals & Biotechnology industry average of 33.60. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, reflecting expectations of either superior earnings growth or a perception of lower risk. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. The market capitalisation of Rs 4,37,986.60 crore further cements its status as a large-cap stalwart within the sector.</p>\n\n                <p><st..."
      },
      {
        "title": "P/E at 34.65 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-amid-nifty-50-membership-and-institutional-shifts-4058490",
        "imagepath": "",
        "date": "2026-06-17 09:22:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Amidst Sector Parity</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> stands at 34.65, marginally above the Pharmaceuticals &amp; Biotechnology industry average of 33.60. This premium, while not extreme, suggests that investors are willing to pay a slight premium for the company’s earnings relative to its peers. Given the sector’s broad performance, with 19 out of 35 stocks reporting positive results, 9 flat, and 7 negative, the valuation appears to reflect a degree of confidence in the company’s earnings stability and growth prospects. However, the premium also invites scrutiny — <a href=\"https://www.marketsmojo.com/sto..."
      },
      {
        "title": "P/E at 34.64 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4055543",
        "imagepath": "",
        "date": "2026-06-16 09:21:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: A Slight Premium Reflecting Sector Confidence</strong></p>\n                <p>The P/E ratio of 34.64 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> sits just above the industry average of 33.60, indicating that investors are willing to pay a small premium for the stock relative to its sector. This premium suggests a perception of stable earnings growth or quality relative to peers, though it is not excessive enough to imply overvaluation concerns. The company’s large-cap status, with a market capitalisation of ₹4,33,319.90 crores, further supports this valuation stance, as large-cap pharmaceutical firms often command steadier multiples due to their scale and diversified pr..."
      }
    ],
    "total": 1154,
    "sid": "948699",
    "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
      "datetime": "20-Jun-2026",
      "details": "Acquisition of Innovcare Lifesciences Private Limited",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Jun-2026",
      "details": "Information about transfer of equity shares and unclaimed dividends to the Investor Education and Protection Fund (IEPF) Account",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "14-Jun-2026",
      "details": "As attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>500%</strong> dividend, ex-date: 07 Jul 26",
          "dt": "2026-07-07",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10",
          "dt": "2010-11-25",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13",
          "dt": "2013-07-29",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

10,956 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Nears Rs 1,900 Strike

2026-06-23 10:00:15

On 23 Jun 2026, 10,956 call contracts at the Rs 1,900 strike price changed hands on Sun Pharmaceutical Industries Ltd, with the stock closing at Rs 1,892. This near at-the-money activity coincides with a 1.80% gain in the cash market, signalling a strong alignment between options positioning and underlying price momentum.

Read full news article

Rs 1,840 Puts — 2.7% Below Current Price — Draw 2,530 Contracts on Sun Pharmaceutical Industries Ltd

2026-06-23 10:00:15

The stock is trading at Rs 1,892, yet put contracts at the Rs 1,840 strike have surged to 2,530 on 23 Jun 2026, signalling a nuanced options market dynamic for Sun Pharmaceutical Industries Ltd. This activity invites a closer look at whether these puts represent hedging, bearish bets, or put writing.

Read full news article

P/E at 35.85 vs Industry's 34.38: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-23 09:21:20

Valuation Picture: Premium Amidst Sector Parity

The current P/E of 35.85 for Sun Pharmaceutical Industries Ltd represents a modest premium of approximately 4.3% over the sector average of 34.38. This premium suggests that investors are willing to pay slightly more for the company’s earnings relative to its peers in Pharmaceuticals & Biotechnology. Given the sector’s broad composition, which includes 35 stocks with 19 reporting positive results, 9 flat, and 7 negative, this premium may reflect confidence in the company’s earnings stability and growth prospects. However, the premium is not excessive, indicating a valuation that remains broadly in li...

Read full news article

P/E at 35.38 vs Industry's 34.06: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-22 09:21:42

Valuation Picture: Premium Amidst Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 35.38, slightly above the Pharmaceuticals & Biotechnology industry average of 34.06. This premium, though not extreme, suggests investors are willing to pay a bit more for the stock relative to its peers. The market capitalisation of ₹4,40,086.02 crore places it firmly in the large-cap category, reflecting its established position within the sector.

This valuation premium may be interpreted as a reflection of the company’s relative stability and growth prospects within a sector that has seen varied results. However,...

Read full news article

Sun Pharmaceutical Industries Ltd is Rated Buy

2026-06-21 10:10:26

Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 8 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

P/E at 35.16 vs Industry's 33.88: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-19 09:21:41

Valuation Picture: Premium Amidst Sector Norms

The current P/E ratio of Sun Pharmaceutical Industries Ltd at 35.16 is approximately 3.8% higher than the industry average of 33.88. This premium suggests that investors are willing to pay a slight premium for the company’s earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. While not an extreme divergence, this elevated valuation may reflect expectations of sustained earnings growth or perceived stability within a large-cap framework valued at ₹4,40,589.88 crores.

However, the premium is not excessive when compared to historical sector valuations, indicati...

Read full news article

P/E at 35.03 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-18 09:22:26

Valuation Picture: Premium Amidst Sector Norms

The current P/E of 35.03 for Sun Pharmaceutical Industries Ltd stands approximately 4.2% above the Pharmaceuticals & Biotechnology industry average of 33.60. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, reflecting expectations of either superior earnings growth or a perception of lower risk. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. The market capitalisation of Rs 4,37,986.60 crore further cements its status as a large-cap stalwart within the sector.

Read full news article

P/E at 34.65 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-17 09:22:03

Valuation Picture: Premium Amidst Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 34.65, marginally above the Pharmaceuticals & Biotechnology industry average of 33.60. This premium, while not extreme, suggests that investors are willing to pay a slight premium for the company’s earnings relative to its peers. Given the sector’s broad performance, with 19 out of 35 stocks reporting positive results, 9 flat, and 7 negative, the valuation appears to reflect a degree of confidence in the company’s earnings stability and growth prospects. However, the premium also invites scrutiny — Read full news article

P/E at 34.64 vs Industry's 33.60: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-06-16 09:21:15

Valuation Picture: A Slight Premium Reflecting Sector Confidence

The P/E ratio of 34.64 for Sun Pharmaceutical Industries Ltd sits just above the industry average of 33.60, indicating that investors are willing to pay a small premium for the stock relative to its sector. This premium suggests a perception of stable earnings growth or quality relative to peers, though it is not excessive enough to imply overvaluation concerns. The company’s large-cap status, with a market capitalisation of ₹4,33,319.90 crores, further supports this valuation stance, as large-cap pharmaceutical firms often command steadier multiples due to their scale and diversified pr...

Read full news article

View All News